Drugs / PLICAMYCIN

Trials 3

2012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/22 trials
Phase 1/2 NCT02859415 Aug → Dec 2019 germ cell tumor, lung neoplasm, mesothelioma, neoplasm of esophagus +1 National Cancer Institute (NCI) Terminated No outcome recorded Stop: Enrollment
Phase 1/2 NCT01610570 May 2012 → May 2014 Ewing sarcoma National Cancer Institute (NCI) Terminated No outcome recorded Stop: Enrollment
Phase 21 trial
Phase 2 NCT01624090 Sep 2012 → Aug 2019 breast cancer, esophageal cancer, lung cancer, mesothelioma National Cancer Institute (NCI) Terminated No outcome recorded Stop: Enrollment

Evidence & citations 15 cited values

Every value below carries the sentence it was read from. 5 sources stand behind the page.

FieldValueCited text
Known as PLICAMYCIN ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as A-2371 ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as ANTIBIOTIC LA-7017 ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as Aureolic acid ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as LA-7017 ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as Mithracin ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as Mithramycin ClinicalTrials.gov intervention name — accepted as the source's own label NCT01610570 ↗
2

NCT01624090 ↗

NCT02859415 ↗

Known as Mithramycin a ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as NSC-24559 ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as PA-144 ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as Plicamicina ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Known as Plicamycine ChEMBL registry synonym — accepted as the source's own label CHEMBL1237054 ↗
Action Inhibit “mithramycin was identified as a potent inhibitor of the Ewing sarcoma EWS-FLI1 transcription factor.” PMID 28735378 ↗ Jul 2017
Modality Small molecule — CHEMBL1237054 ↗
Route Intravenous “Mithramycin was administered intravenously over 6 h once daily for 7 days for 28 day cycles.” PMID 28735378 ↗ Jul 2017